Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
electroCore, Inc. (Nasdaq: ECOR) announced a $6.0 million grant from the National Institute on Drug Abuse for a pivotal clinical trial of its gammaCore nVNS device to treat opioid use disorder (OUD). The trial, to be conducted at Emory University and Georgia Institute of Technology, will enroll approximately 100 patients and evaluate the efficacy of gammaCore in reducing opioid withdrawal symptoms. Dr. Douglas Bremner noted the significance of this research as there are limited effective treatments for OUD. Peter Staats, CMO of electroCore, emphasized the potential of gammaCore to alleviate withdrawal pain and reduce healthcare costs. The study follows promising pilot data highlighting the device's ability to decrease both psychological and physiological withdrawal symptoms.
electroCore (Nasdaq: ECOR) has announced results from a clinical trial that highlights the efficacy of its gammaCore non-invasive vagus nerve stimulation (nVNS) in enhancing second language learning. Conducted at the Defense Language Institute (DLI) and supported by DARPA, the study involved 36 participants learning Arabic. Results showed that those using gammaCore exhibited significantly improved language recall compared to a sham group (p=0.025). Additionally, participants reported enhanced energy (p=0.036) and focus (p=0.001) throughout the training. The trial's findings suggest potential applications for military training and cognitive performance improvement. The study represents a critical advancement for electroCore's nVNS technology, which aims to promote overall wellbeing.
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine company, will announce its financial results for Q1 2023 on May 3, 2023, after market close. A conference call will be held at 4:30 PM EDT to discuss results and answer questions. The company focuses on non-invasive vagus nerve stimulation (nVNS) technology for managing medical conditions and enhancing wellbeing. electroCore aims to commercialize medical devices and consumer products in the U.S. and selected international markets.